Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

Establishment Labs (NASDAQ:ESTA) Stock Price Target Cut by TD Cowen

Establishment Labs logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

Establishment Labs (NASDAQ:ESTA - Get Free Report) had its price objective lowered by research analysts at TD Cowen from $117.00 to $95.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm presently has a "buy" rating on the stock. TD Cowen's price objective suggests a potential upside of 42.59% from the company's current price.

Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. upped their price target on shares of Establishment Labs from $84.00 to $95.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Mizuho lifted their price objective on Establishment Labs from $100.00 to $105.00 and gave the company an "outperform" rating in a research note on Wednesday, July 15th. Needham & Company LLC boosted their price objective on Establishment Labs from $86.00 to $95.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Weiss Ratings restated a "sell (e+)" rating on shares of Establishment Labs in a research note on Monday, September 21st. Finally, Canaccord Genuity Group set a $105.00 target price on Establishment Labs in a research note on Thursday, August 6th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $96.11.

View Our Latest Stock Analysis on ESTA

Establishment Labs Stock Up 4.4%

NASDAQ ESTA traded up $2.82 on Monday, hitting $66.62. The stock had a trading volume of 77,630 shares, compared to its average volume of 510,428. Establishment Labs has a 52-week low of $47.00 and a 52-week high of $97.59. The business's fifty day moving average price is $67.87 and its 200 day moving average price is $74.62. The company has a debt-to-equity ratio of 12.11, a current ratio of 3.84 and a quick ratio of 2.52. The stock has a market cap of $1.99 billion, a price-to-earnings ratio of -50.76 and a beta of 1.06.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The company had revenue of $67.54 million for the quarter, compared to analyst estimates of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The business's revenue was up 31.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.57) EPS. Equities research analysts anticipate that Establishment Labs will post -1.08 earnings per share for the current year.

Hedge Funds Weigh In On Establishment Labs

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC increased its stake in shares of Establishment Labs by 849.5% in the 3rd quarter. Sterling Capital Management LLC now owns 902 shares of the company's stock worth $58,000 after acquiring an additional 807 shares during the last quarter. State of Alaska Department of Revenue purchased a new position in shares of Establishment Labs during the 3rd quarter worth $80,000. Engineers Gate Manager LP boosted its position in shares of Establishment Labs by 7.5% during the 2nd quarter. Engineers Gate Manager LP now owns 31,458 shares of the company's stock valued at $2,699,000 after acquiring an additional 2,191 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Establishment Labs during the 2nd quarter valued at about $32,000. Finally, NewEdge Advisors LLC boosted its position in shares of Establishment Labs by 34.9% during the 2nd quarter. NewEdge Advisors LLC now owns 13,871 shares of the company's stock valued at $1,190,000 after acquiring an additional 3,587 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company's stock.

Establishment Labs Company Profile

(Get Free Report)

Establishment Labs Holdings Inc is a medical technology company focused on women's health and the breast aesthetics market. The company develops, manufactures and commercializes breast implants and related technologies designed for breast augmentation, reconstruction and revision procedures.

Its product portfolio includes the Motiva line of breast implants, which incorporates the company's proprietary implant materials, surface technologies and design features. Establishment Labs also offers Motiva Flora tissue expanders for use in breast reconstruction and has developed Mia Femtech, a minimally invasive breast enhancement procedure intended to provide a less invasive alternative to traditional augmentation techniques.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves physicians, hospitals and patients in international markets.

Featured Articles

Analyst Recommendations for Establishment Labs (NASDAQ:ESTA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Establishment Labs Right Now?

Before you consider Establishment Labs, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.

While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines